Chimérický antigenní receptor T lymfocytů - genová terapie budoucnosti u nádorových onemocnění?
[Chimeric Antigen Receptor T-cells - Gene Therapy of the Future for Malignant Diseases?]
Language Czech Country Czech Republic Media print
Document type English Abstract, Journal Article, Review
PubMed
26647888
DOI
10.14735/amko20154s44
PII: 56682
- MeSH
- Genetic Therapy * MeSH
- Humans MeSH
- Neoplasms therapy MeSH
- Receptors, Antigen, T-Cell genetics MeSH
- Recombinant Fusion Proteins genetics MeSH
- T-Lymphocytes immunology metabolism MeSH
- Check Tag
- Humans MeSH
- Publication type
- English Abstract MeSH
- Journal Article MeSH
- Review MeSH
- Names of Substances
- Receptors, Antigen, T-Cell MeSH
- Recombinant Fusion Proteins MeSH
Chimeric antigen receptors are synthetic, genetically modified receptors of T-cells. The introduction of chimeric antigen receptors into autologous patient T-cells can redirect the lymphocytes to specific antigen targets on the surface of malignant cells. This has recently emerged as an intriguing therapy approach in both hematologic malignancies and later also in solid tumors. Various chimeric antigen receptor designs and manufacturing processes were developed and seem to have a strong impact on the activity of chimeric antigen receptor T-lymphocytes and thereby the therapy success. The individual variables are currently being tested in numerous clinical trials. In this review, I will briefly describe the principle, basic structure and construction of chimeric antigen receptor T-lymphocytes.
References provided by Crossref.org